245 related articles for article (PubMed ID: 33677674)
21. The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH.
Zwicker JI; Wang TF; DeAngelo DJ; Lauw MN; Connors JM; Falanga A; McMasters M; Carrier M
J Thromb Haemost; 2020 Feb; 18(2):278-284. PubMed ID: 31999063
[TBL] [Abstract][Full Text] [Related]
22. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
Horvat TZ; Pecoraro JJ; Daley RJ; Buie LW; King AC; Rampal RK; Tallman MS; Park JH; Douer D
Leuk Res; 2016 Nov; 50():17-20. PubMed ID: 27631159
[TBL] [Abstract][Full Text] [Related]
23. An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events.
Farrell K; Fyfe A; Allan J; Tait RC; Leach M
Leuk Lymphoma; 2016 Nov; 57(11):2568-74. PubMed ID: 27078747
[TBL] [Abstract][Full Text] [Related]
24. Venous thromboembolism in adults treated for acute lymphoblastic leukaemia: Effect of fresh frozen plasma supplementation.
Lauw MN; Van der Holt B; Middeldorp S; Meijers JC; Cornelissen JJ; Biemond BJ
Thromb Haemost; 2013 Apr; 109(4):633-42. PubMed ID: 23364346
[TBL] [Abstract][Full Text] [Related]
25. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
Christ TN; Stock W; Knoebel RW
J Oncol Pharm Pract; 2018 Jun; 24(4):299-308. PubMed ID: 28355969
[TBL] [Abstract][Full Text] [Related]
26. Obesity and risk for venous thromboembolism from contemporary therapy for pediatric acute lymphoblastic leukemia.
Prasca S; Carmona R; Ji L; Ko RH; Bhojwani D; Rawlins YA; Mittelman SD; Young G; Orgel E
Thromb Res; 2018 May; 165():44-50. PubMed ID: 29567586
[TBL] [Abstract][Full Text] [Related]
27. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia.
Larson RA; Fretzin MH; Dodge RK; Schiffer CA
Leukemia; 1998 May; 12(5):660-5. PubMed ID: 9593262
[TBL] [Abstract][Full Text] [Related]
28. Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemia.
Mateos MK; Trahair TN; Mayoh C; Barbaro PM; Sutton R; Revesz T; Barbaric D; Giles JE; Alvaro F; Mechinaud F; Catchpoole D; Kotecha RS; Dalla-Pozza L; Quinn MCJ; MacGregor S; Chenevix-Trench G; Marshall GM
Thromb Res; 2019 Jun; 178():132-138. PubMed ID: 31030032
[TBL] [Abstract][Full Text] [Related]
29. A retrospective study of venous thromboembolism in acute leukemia patients treated at the University of Texas MD Anderson Cancer Center.
Vu K; Luong NV; Hubbard J; Zalpour A; Faderl S; Thomas DA; Yang D; Kantarjian H; Kroll MH
Cancer Med; 2015 Jan; 4(1):27-35. PubMed ID: 25487644
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Derman BA; Streck M; Wynne J; Christ TN; Curran E; Stock W; Knoebel RW
Leuk Lymphoma; 2020 Mar; 61(3):614-622. PubMed ID: 31680584
[TBL] [Abstract][Full Text] [Related]
31. PEGylated
Verma A; Chen K; Bender C; Gorney N; Leonard W; Barnette P
Pediatr Hematol Oncol; 2019 Aug; 36(5):277-286. PubMed ID: 31296092
[TBL] [Abstract][Full Text] [Related]
32. A systematic review and meta-analysis of the effectiveness of primary thromboprophylaxis in acute lymphoblastic leukemia during early-phase therapy including asparaginase or its prolonged form.
Hu Z; Persaud Y; Ahuja S
Crit Rev Oncol Hematol; 2024 May; 197():104347. PubMed ID: 38583546
[TBL] [Abstract][Full Text] [Related]
33. The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia.
Grace RF; DeAngelo DJ; Stevenson KE; Neuberg D; Sallan SE; Mourad YRA; Bergeron J; Seftel MD; Kokulis C; Connors JM
J Thromb Thrombolysis; 2018 Feb; 45(2):306-314. PubMed ID: 29260426
[TBL] [Abstract][Full Text] [Related]
34. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia.
Aldoss I; Douer D; Behrendt CE; Chaudhary P; Mohrbacher A; Vrona J; Pullarkat V
Eur J Haematol; 2016 Apr; 96(4):375-80. PubMed ID: 26095294
[TBL] [Abstract][Full Text] [Related]
35. Thromboembolism prophylaxis during L-asparaginase therapy in acute lymphoblastic leukemia - time to reconsider current approaches?
Fulcher J; Carrier M
Thromb Res; 2020 Apr; 188():100-102. PubMed ID: 32120278
[TBL] [Abstract][Full Text] [Related]
36. Clinical and demographic factors contributing to asparaginase-associated toxicities in children with acute lymphoblastic leukemia.
Dharia P; Swartz MD; Bernhardt MB; Chen H; Gramatges MM; Lupo PJ; Brown AL; Scheurer ME
Leuk Lymphoma; 2022 Dec; 63(12):2948-2954. PubMed ID: 35895075
[TBL] [Abstract][Full Text] [Related]
37. The Incidence of Hypersensitivity Reactions to Pegylated Asparaginase in Children With Acute Lymphoblastic Leukemia: A City-wide Experience.
Alrazzak M; Beaupin LK; Kinyoun P; Barth M
J Pediatr Hematol Oncol; 2016 Jan; 38(1):e16-20. PubMed ID: 26558809
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia.
Ribera JM; Morgades M; Montesinos P; Martino R; Barba P; Soria B; Bermúdez A; Moreno MJ; González-Campos J; Vives S; Gil C; Abella E; Guàrdia R; Martínez-Carballeira D; Martínez-Sánchez P; Amigo ML; Mercadal S; Serrano A; López-Martínez A; Vall-Llovera F; Sánchez-Sánchez MJ; Peñarrubia MJ; Calbacho M; Méndez JA; Bergua J; Cladera A; Tormo M; García-Belmonte D; Feliu E; Ciudad J; Orfao A;
Leuk Lymphoma; 2018 Jul; 59(7):1634-1643. PubMed ID: 29165013
[TBL] [Abstract][Full Text] [Related]
39. Evaluation for inherited and acquired prothrombotic defects predisposing to symptomatic thromboembolism in children with acute lymphoblastic leukemia: a protocol for a prospective, observational, cohort study.
Athale UH; Laverdiere C; Nayiager T; Delva YL; Foster G; Thabane L; Chan AK
BMC Cancer; 2017 May; 17(1):313. PubMed ID: 28472942
[TBL] [Abstract][Full Text] [Related]
40. Prolonged
Mondelaers V; Suciu S; De Moerloose B; Ferster A; Mazingue F; Plat G; Yakouben K; Uyttebroeck A; Lutz P; Costa V; Sirvent N; Plouvier E; Munzer M; Poirée M; Minckes O; Millot F; Plantaz D; Maes P; Hoyoux C; Cavé H; Rohrlich P; Bertrand Y; Benoit Y;
Haematologica; 2017 Oct; 102(10):1727-1738. PubMed ID: 28751566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
